ADMA Biologics (NASDAQ:ADMA) saw its stock price plummet 10.73% in after-hours trading on Wednesday following the release of its second-quarter financial results. The biopharmaceutical company's earnings met expectations, but sales fell short of analyst estimates, triggering the sharp decline.

ADMA reported quarterly earnings of $0.14 per share, in line with analyst consensus estimates and representing a 7.69% increase from the same period last year. However, the company's quarterly sales of $121.98 million missed the analyst consensus estimate of $122.67 million by 0.56%. Despite the miss, this still marks a 13.80% increase over sales of $107.19 million in the same period last year.

While ADMA Biologics reaffirmed its fiscal year 2025-2026 guidance for total revenue, adjusted EBITDA, and adjusted net income, investors appear to be focusing on the sales miss. The significant after-hours drop suggests that market participants may have been expecting stronger results or were disappointed by the company's performance relative to expectations, despite the year-over-year growth. The reaction highlights the market's sensitivity to even slight misses in revenue projections, particularly for growth-oriented biopharmaceutical companies.